Atlas
Market PulseMovers & ShakersSector ViewStocksETFFundsPortfoliosAdmin
Atlas › Stocks › AARTIPHARM

AARTIPHARM

Aarti Pharmalabs Limited
Micro-capPharma ↗

What the six lenses say about AARTIPHARM — its relative strength vs the baselines, price & RS trend, the 8-quarter financials, and live filings.

Price
₹862.6
2026-09-08
VWAP · 1Y anchor
₹777
+11.0% from VWAP
P/E · TTM
41.9×
TTM EPS ₹20.6
52-week range
78%
position low→high
RSI(14)
63
momentum

Own sector index

Pharma ↗
Overweight

1M

+0.4%

3M

+10.5%

1Y

+22.0%

Breadth >EMA21

56%

How AARTIPHARM’s own sector index is moving — context for reading the stock’s six lenses.

Six-lens read

What the six lenses say

How the lenses are scored ↗
Strength
5.5
avg conviction decile
Leadership
—
top-decile composite in cohort
Each lens is a decile within its cap cohort (D10 = top 10%) — no black-box composite. Expand a lens for the real numbers behind it.
LensDecile · Micro-cap cohortDRaw
TechnicalD10100›

The actual numbers

Price vs VWAP (1y)+11.0%
EMA trend stackUp · 21>50>200
Price vs 200-EMA+16.6%
Price vs 50-EMA+10.9%
RSI(14)63
RS vs Nifty 500 · 3M+37.8%
RS vs sector · 3M+31.8%
52-week range78%
Volume vs 30d avg0.43×
Volume vs 60d avg0.75×
ATR(14) · volatility39.6
Bollinger width · vol contraction0.101
FundamentalD328›

The actual numbers

Return on equity (ROE)8.8%
Operating margin16.3%
Net margin10.3%
Revenue growth · YoY-14.0%
EPS growth · YoY-31.6%
Debt / equity0.35×

Full 8-quarter history in the financials table below.

ValuationD317›

The actual numbers

P/E (TTM)41.9×
TTM EPS₹20.6
52-week range78%
CatalystD431›

The actual numbers

Earnings & momentum24
Capital actions23
Governance75

Every filing in the corporate-announcements panel below.

FlowD132›

The actual numbers

Promoter holding43.1%
Delivery · 30d avg41.3%
Up/down-day asymmetry-4.0pp
How the decile & conviction are calculated

Decile — each lens’s 0–100 score is ranked against every Micro-cap stock in the universe. D10 = top 10% (strongest), D1 = bottom 10%. A decile is simply where this stock sits versus its size-peers on that lens — no weighting, no black box.

Conviction — the average of the two active conviction-lens deciles (Technical & Flow):

( D10 + D1 ) ÷ 2 = 5.5(Technical · Flow)

Fundamental, Catalyst, Valuation and Policy are shown for context but carry weight 0 in the current model, so they are not scored into conviction. Full detail on the methodology page ↗.

Glass box

How the score is built

Click a lens to expand its sub-components, then drill to the actual values. The eye icon on any term explains it.

Conviction score · Highest
93
Conviction score 93/100 · avg-decile strength 5.5/10
Conviction score93/100›
TechnicalD10›
FundamentalD3›
ValuationD3›
CatalystD4›
FlowD1›

Policy

Government policy · Pharma

Active policies relevant to this sector — flagged as a Red / Amber / Green signal, not scored into the six-lens conviction. The lenses say what the market is doing; policy is context for why.

Tailwind· HIGH impact

PLI Scheme — Pharmaceuticals & API

Production-linked incentive scheme for pharmaceuticals, APIs, and medical devices

Relative strength · always on

Percentage-point spread vs each baseline across six windows. Green = outperforming, red = lagging. Data as of 2026-09-08.

Baseline1D1W1M3M6M12M
Nifty 50
Large-cap anchor
+0.9pp
+3.3pp
+28.1pp
+39.4pp
+26.0pp
+1.9pp
Nifty 500
Broad-market baseline
+0.9pp
+3.3pp
+27.0pp
+37.8pp
+20.2pp
-3.4pp
Sector
Own-sector index
—
—
+24.2pp
+31.8pp
+7.1pp
-24.1pp

From atlas_foundation.technical_daily. Sector row covers 1M–12M (1D/1W not stored).

Trend

Price · EMA 20 / 50 / 200

AARTIPHARM daily close with the three trend EMAs · atlas_foundation.ohlcv_stock.

₹ (close)
862.65+3.85

Relative strength

RS vs baseline · rebased to 100

AARTIPHARM ÷ Nifty 500, rebased to 100 at window start — above 100 = outperforming since then.

RS vs Nifty 500 (=100)
129.10+1.12

TradingView composite technical analysis — multi-timeframe consensus

Quarterly financials

Last 8 quarters from the company’s filings (₹ crore) — revenue, profit, margins and the growth trend.

MetricJun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26
Revenue (₹cr)555458538564386418432583
↳ change QoQ—-17.5%+17.4%+4.9%-31.6%+8.3%+3.3%+35.0%
EBITDA (₹cr)99981341469374102113
EBITDA margin17.8%21.4%24.9%25.9%24.1%17.7%23.6%19.4%
PAT (₹cr)5555748850284861
↳ change QoQ—-1.5%+35.5%+18.9%-43.2%-44.0%+71.4%+27.1%
Net margin10.0%11.9%13.8%15.6%13.0%6.7%11.1%10.5%
EPS (₹)6.126.038.169.755.463.085.296.74
D/E————————
YoY growth · Mar '26Revenue +3.4% YoYPAT -30.7% YoY

Corporate announcements

Filings to the exchange — capital actions, earnings and governance. Most recent first.

  • 2 Sep '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 31 Aug '26
    MEDIUMgovernance
    Resignation of Director/KMP/SMP
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 31 Aug '26
    LOWgovernance
    Change in Management
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 29 Aug '26
    LOWgovernance
    Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 17 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 10 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 10 Aug '26
    MEDIUMearnings
    Investor Presentation
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 7 Aug '26
    MEDIUMgovernance
    Change in Director(s)
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 7 Aug '26
    LOWgovernance
    Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 7 Aug '26
    MEDIUMgovernance
    Change in Director(s)
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 7 Aug '26
    HIGHearnings
    Outcome of Board Meeting
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 3 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 30 Jun '26
    MEDIUMcapital
    Press Release
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 24 Jun '26
    LOWgovernance
    Allotment of Securities
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 22 Jun '26
    MEDIUMgovernance
    Disclosure under SEBI Takeover Regulations
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗

…and 5 more.

Ownership

Who holds AARTIPHARM

Mutual funds holding AARTIPHARM (4)

FundWeightAUM ₹crGrade
UTI Healthcare Reg Gr0.73%1,371
WhiteOak Capital Phrm and Hlthcr Reg Gr0.85%825
Taurus Flexi Cap Gr0.80%369
Unifi Flexi Cap Reg Gr1.25%227

ETFs holding AARTIPHARM (0)

No tracked ETF holds AARTIPHARM ≥0.5%.

Show company profile (about, sector, employees, IPO)
Native from atlas_foundation — lens journal, technical_daily, ohlcv_stock; TradingView for the live instrument view. ← Back to Pharma